SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?


To: BIGFRED who wrote (1419)8/3/1998 10:21:00 PM
From: Andrew T  Respond to of 4650
 
biomoda.com
CORPORATE MILESTONES:

November, 1995

University of California awards Biomoda a worldwide,
exclusive Patent License to TCPP technology for detecting
and treating lung cancer.

January, 1995

Biomoda and the University of California enter into a
Small Business Cooperative Research and Development
Agreement to be conducted by Los Alamos National
Laboratory on production of radioactive copper.

January, 1996

Biomoda and Shanghai Center for Research and
Development sign a Letter of Intent to establish a joint
venture to research and develop, manufacture and market
lung cancer detection and treatment products in the
People's Republic of China.

September, 1997

Los Alamos National Laboratory reports to Biomoda the
results of their work on the Cooperative Research and
Development Agreement (CRADA). Los Alamos
demonstrated a low energy production technology capable
of producing radioactive copper (67Cu) with medical
isotope generators, a significant enabling technology for
the commercialization of Biomoda's in vivo diagnostic
and therapeutic products.

April, 1998

Advanced Optics Electronics, Inc. (stock symbol ADOT)
completes seed capital equity investment in Biomoda.


Pending:
60-patient study to evaluate sensitivity and specificity of
Biomoda's technology for detecting lung cancer in sputum
specimens. Anticipated to start: Summer, 1998.



To: BIGFRED who wrote (1419)8/3/1998 10:29:00 PM
From: Andrew T  Read Replies (1) | Respond to of 4650
 
Hello all,
If you read this press release from beginning to end it states two different amounts for which is Adots "position" in Biomoda.
Advanced Optics Electronics, Inc.

News Release

Biomoda, Inc. in Discussions with Major German Pharmaceutical Affiliate,
Discloses Biomoda Partner Advanced Optics

Advanced Optics to Become Fully Reporting by July 15, 1998

Albuquerque, N.M. - (Business Wire) B June 8, 1998 B Advanced Optics Electronics, Inc. today disclosed that
BIOMODA, Inc. (in which Advanced Optics Electronics, Inc. also owns approximately 22% of stock and holds an
option to increase that position to approximately 27% ) has been contacted by BERLEX LABORATORIES on behalf
of its parent company, SCHERING AG. Schering AG is a German-based pharmaceutical and medical technology
company headquartered in Berlin.

Schering AG, with over $3.8 Billion ($U.S.) in annual revenues and offices world-wide, is a recognized leader in
biotechnology research and the use of contrast media in the diagnosis and treatment of a variety of diseases.

Biomoda, Inc., a privately held emerging biotechnology company, holds an exclusive world-wide license for
patented tests for the very early detection of lung cancer. Biomoda's sputum test, capable of detecting lung cancer at
least six (6) years earlier than any currently available test, is uniquely integrated with an effective lung cancer
treatment utilizing the same technology.

Preliminary discussions have recently been held between representatives of Berlex Labs in Wayne, NJ and
representatives of Biomoda, Inc. Berlex/Schering AG specializes in early diagnosis and therapy, two key areas
addressed in Biomoda's cancer testing and treatment program.

Schering AG invests approximately $700 Million annually in research and development. Of this amount, about 25%
is used in collaboration with new and emerging technologies and companies.

Berlex/Schering will make a determination on how best to proceed with Biomoda upon completion of Biomoda's
testing of its early cancer test and treatment program. Biomoda is currently conducting tests at a respected
cytopathology lab in Arizona. Biomoda expects to complete its series of tests within twelve weeks.

In other Company news, Advanced Optics Electronics, Inc. expects to become a fully reporting company with the
SEC as of July 15, 1998. A company spokesperson stated that, as a fully reporting company, ADOT positions itself
to be followed by analysts and brokers in the investment community, both domestically and internationally.

Advanced Optics Electronics, Inc. (OTC BB: ADOT-news) is a developer of patented electronic display technology,
utilizing ADOT's proprietary SLM (Spatial Light Modulator) light valve. This industry-leading technology can be
utilized in many diverse fields including the production of "television quality" advertising billboards, medical testing
equipment, military displays, computer monitors and high definition video transmission. Advanced Optics
Electronics, Inc. actively seeks partnerships with companies in fields that could benefit from ADOT's patented
technology. ADOT also owns a 27% interest in Biomoda, Inc., an emerging biotechnology company specializing in
breakthrough cancer diagnostics and therapy. Advanced Optics Electronics, Inc. has retained first right of refusal to
design, manufacture and distribute the necessary scanning testing devices for the lung cancer test using Advanced
Optics Electronics, Inc. proprietary display technology.

This press release contains forward-looking statements with respect to the results of operations and business of the
Company that involves risk and uncertainties. The Company's actual future results could materially differ from
those discussed. Risks and uncertainties of the Company will be detailed from time to time in the Company's
periodic reports to be filed with the Securities and Exchange Commission.



SHAREHOLDER RELATIONS NOTE

ADOT will promptly respond to all requests for information from shareholders and the general public, shareholders
will receive priority response. All such requests must be sent to ADOT via FAX: (505) 858-1871 or U.S. Mail to
8301Washington Ave. Building 4, Albuquerque, NM 87113. All such requests must include the Name, Daytime
Fax (if available) and Street Address as box numbers cannot be accepted.

This policy is necessitated by the very large number of Internet postings and inquiries, many with pen names which
have caused ADOT and other related companies to be overwhelmed with anonymous comments, requests and
demands.

Contact Advanced Optics Electronics Inc. at 505/797-7878 or visit their Web site at adot.org.

Categories: aerospace/Defense, Biotechnology, Computers/Electronics, Medicine, Pharmaceutical,
Telecommunications.



To: BIGFRED who wrote (1419)8/3/1998 10:33:00 PM
From: Andrew T  Respond to of 4650
 
From what I see on the Biomoda homepage is that ADOT has COMPLETED THEIR investment in Biomoda

<April, 1998
Advanced Optics Electronics, Inc. (stock symbol ADOT)
completes seed capital equity investment in Biomoda.>



To: BIGFRED who wrote (1419)8/3/1998 10:36:00 PM
From: Luminous  Respond to of 4650
 
This deception, intentional or not, is keeping me from purchasing more ADOT for now, and may be contributing to these bargain prices. Deception is a very good reason to overlook potential. What else has been or will be exaggerated???

An explanation from ADOT might help... as it looks like ADOT got caught stretching the truth, and is quietly covering it up.



To: BIGFRED who wrote (1419)8/4/1998 9:08:00 AM
From: garyb  Respond to of 4650
 
BIGFRED
Thanks for clearing that up for me. I will review the website again.
Regards
Garyb